Margaret Barnich

Suggest Changes
Learn More
BACKGROUND To estimate the response rate and therapy related toxicities of the anti-CD20 monoclonal antibody rituximab when combined with chemotherapy including ifosfamide, carboplatin, and etoposide(More)
  • 1